<DOC>
	<DOCNO>NCT02317627</DOCNO>
	<brief_summary>This study do evaluate safety , tolerability , activity , pharmacokinetics ( PK ) , daily dose regimen KD025 administer orally 12 week subject psoriasis vulgaris fail least one line systemic therapy .</brief_summary>
	<brief_title>Study KD025 Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Able provide write informed consent prior performance study specific procedure Has diagnosis moderately severe plaque psoriasis moderately stable 6 month fail least one line systemic phototherapy candidate additional systemic therapy Has PASI ≥ 12 within 24hour period prior first dose study drug Has least 10 % body surface area affect plaque psoriasis within 24hour period prior first dose study drug Willing avoid tan device Willing forgo systemic topical treatment psoriasis course study Adequate bone marrow function Negative urine pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose study drug Must agree use highly effective method birth control ( &lt; 1 % per year failure rate ) study 1 month termination study . Effective birth control include implant , injectables , combine oral contraceptive , IUDs , sexual abstinence , vasectomized partner Willing complete study measurement assessment compliance protocol Has nonplaque druginduced ( antimalarial , lithium ) psoriasis ( If subject take angiotensin II receptor blocker beta blocker dos must stable 6 month prior study entry ) Use corticosteroid immunosuppressive therapy within 4 week prior study entry except Class 5 weak topical corticosteroid immunosuppressive therapy face , groin , scalp . Use methotrexate , acitretin , cyclosporine within 4 week prior study entry Using phototherapy within 4 week prior study entry Using biologic therapy , include antibody IL17 , within 3 month prior study entry Has concomitant condition require treatment moderate high dose steroid 12 week prior screen Has viral , fungal , bacterial skin infection Is pregnant lactate woman History gastrointestinal ( GI ) surgery include bariatric surgery , gastrointestinal condition might interfere drug absorption Currently participate another study investigational drug within 28 day study entry Has history evidence severe illness condition would make subject , opinion investigator , unsuitable study ( poorly control psychiatric disease coronary artery disease ) Regular excessive use alcohol within 2 year prior study entry define alcohol intake &gt; 14 drink per week man &gt; 7 drink per week woman . Approximately 10 g alcohol equal one `` drink '' unit . One unit equal 1 ounce distil spirit , one 12ounce beer , one 4ounce glass wine History presence following : 1 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.0 × upper limit normal ( ULN ) screening . ( Subjects isolate AST elevation magnitude , ratio AST : ALT &gt; 1.5 interviewed regard use alcohol , level repeat participation study discuss medical monitor . ) 2 . Renal disease and/or serum creatinine &gt; 1.5 × ULN screening Has QTc ( F ) interval ( QT interval data correct use Fridericia 's formula ) &gt; 450 msec screen predose ECG Has previous exposure KD025 know allergy/sensitivity KD025 ROCK2 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>